Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 18;14(20):5105.
doi: 10.3390/cancers14205105.

The Role of ctDNA in Gastric Cancer

Justin Mencel  1 , Susanna Slater  1 , Elizabeth Cartwright  1 , Naureen Starling  1
Affiliations
Review

The Role of ctDNA in Gastric Cancer

Justin Mencel et al. Cancers (Basel). .

Abstract

Circulating tumour DNA (ctDNA) has potential applications in gastric cancer (GC) with respect to screening, the detection of minimal residual disease (MRD) following curative surgery, and in the advanced disease setting for treatment decision making and therapeutic monitoring. It can provide a less invasive and convenient method to capture the tumoural genomic landscape compared to tissue-based next-generation DNA sequencing (NGS). In addition, ctDNA can potentially overcome the challenges of tumour heterogeneity seen with tissue-based NGS. Although the evidence for ctDNA in GC is evolving, its potential utility is far reaching and may shape the management of this disease in the future. This article will review the current and future applications of ctDNA in GC.

Keywords: ctDNA; gastric cancer; liquid biopsy.

PubMed Disclaimer

Conflict of interest statement

J.M., S.S., E.C., no conflict of interest; N.S., Advisory Board-Pfizer, AstraZeneca, Servier, MSD. Research funding-AstraZeneca, BMS, Pfizer. Honoraria-Eli Lilly, Merck Serono, MSD Oncology, Pierre Fabre, Servier, GSK, Amgen.

References

    1. Rawla P., Barsouk A. Epidemiology of Gastric Cancer: Global Trends, Risk Factors and Prevention. Prz. Gastroenterol. 2019;14:26–38. doi: 10.5114/pg.2018.80001. - DOI - PMC - PubMed
    1. Bernards N., Creemers G.J., Nieuwenhuijzen G.A.P., Bosscha K., Pruijt J.F.M., Lemmens V.E.P.P. No Improvement in Median Survival for Patients with Metastatic Gastric Cancer despite Increased Use of Chemotherapy. Ann. Oncol. 2013;24:3056–3060. doi: 10.1093/annonc/mdt401. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654. - DOI - PubMed
    1. Lordick F., Carneiro F., Cascinu S., Fleitas T., Haustermans K., Piessen G., Vogel A., Smyth E.C. Gastric Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. Ann. Oncol. 2022 doi: 10.1016/j.annonc.2022.07.004. - DOI - PubMed
    1. Ajani J.A., D’Amico T.A., Bentrem D.J., Chao J., Cooke D., Corvera C., Das P., Enzinger P.C., Enzler T., Fanta P., et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2022;20:167–192. doi: 10.6004/jnccn.2022.0008. - DOI - PubMed

LinkOut - more resources